Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Nov 10 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

This innovative drug is the only approved treatment for Non-Alcoholic Steato Hepatitis and Non-Alcoholic Fatty Liver Disease in the country. Under the agreement, Torrent will market the drug under the brand name VORXAR, while Zydus will continue to market it under its existing brand names.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 10, 2023, titled "Zydus and Torrent sign licensing agreement for co-marketing Saroglitazar Mg, a critical treatment for chronic liver diseases in India".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases